GliomaEarly Phase 1NCT05045027
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
A Early Phase 1 study testing Biospecimen Collection, Diagnostic Imaging and Magnetic Resonance Imaging in people with Glioma and Malignant Glioma, run by Jonsson Comprehensive Cancer Center at 1 site in United States.
Trial summary
This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Glioma, Malignant Glioma, Recurrent Glioma
- What is being tested?
- Biospecimen Collection, Diagnostic Imaging and Magnetic Resonance Imaging
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2021to 10 Sep 2027
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- AIM 1: Healthy volunteers with no evidence of brain tumors or neurologic disease
- AIM 1: Age 18+
- AIM 2: Newly diagnosed or recurrent suspected or confirmed glioma (low or high grade)
- AIM 2: 10 IDH mutant and 10 IDH wild type gliomas
- AIM 2: Clinically indicated for resective surgery or biopsy
- AIM 2: Age 18+
Show all 9Show fewer
- AIM 2: Tumor size > 1x1x1 cm (measurable)
- AIM 3: Recurrent glioma enrolled in an immunotherapy trial or clinically indicated to receive immunotherapy including anti-PD1
- AIM 3: Age 18+
Who cannot join
- AIM 1: Cannot safely perform an MRI
- AIM 1: Age < 18
- AIM 2: Cannot safely perform an MRI or use of MRI contrast agents
- AIM 2: Age < 18
- AIM 3: Cannot safely perform an MRI or use of MRI contrast agents
- AIM 3: Age < 18
Trial locations and contacts
1 site in 1 country.
United States1 site
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095
About this study
Official title: Simultaneous Multinuclear (Na+/H+) Metabolic MRI in Brain Tumors
This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.
Read the detailed description
PRIMARY OBJECTIVES:
- Construct and test a novel multinuclear Na+-H+ metabolic MRI sequence with sensitivity to Sodium (Na+) concentration, Potential of Hydrogen (pH), and oxygen (O2).
II. Correlate Na+-, pH-, and O2-weighted MR image measurements with sodium-proton exchanger isoform-1 (NHE1) immunohistochemistry (IHC), bioenergetics, and gene expression using stereotactic image-guided biopsies from human brain tumors.
III. Quantify changes in Na+-, pH-, and O2-weighted MR images after neoadjuvant anti-PD-1 immunotherapy in recurrent glioblastoma (GBM) and explore associated changes in tumor biology.
OUTLINE:
AIM 1: Previous scan data from healthy subjects is collected and analyzed.
AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis.
AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection.
- Conditions
- Glioma, Malignant Glioma, Recurrent Glioma, Recurrent Malignant Glioma
- Being tested
- Biospecimen Collection, Diagnostic Imaging, Magnetic Resonance Imaging
- Medical subject headings
- Glioma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biospecimen CollectionProcedure or surgery
Also called Biological Sample Collection
Undergo collection of tissue samples
Diagnostic ImagingProcedure or surgery
Also called Medical Imaging
Undergo multinuclear metabolic imaging
Magnetic Resonance ImagingProcedure or surgery
Also called Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI
Undergo MRI
| Study group | Role | What they receive |
|---|---|---|
| Basic science (MRI, metabolic imaging, tissue collection) | Experimental | AIM 1: Previous scan data from healthy subjects is collected and analyzed.
AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis.
AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection. Receives: Procedure: Biospecimen Collection; Procedure: Diagnostic Imaging; Procedure: Magnetic Resonance Imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total sodium concentration
Will calculate NaT using standard methodology and normalize it to ocular Na+ concentration, a constant 135 mmol/l. Will then test whether healthy tissue has a coefficient of variance (COV) of < 10% across all 20 subjects.
Measured: Up to 5 years
NHE1 expression
Will create a comprehensive map of genes/pathways and unique cell subsets associated with NHE1 expression.
Measured: Up to 5 years
Tumor metabolism
Will examine the correlation between baseline tumor metabolism and change in metabolism with respect to overall survival using Cox multivariable regression.
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2021
- Study start1 Sep 2021
- Primary completion15 Nov 2023
- Study completion10 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GliomaStudies of the same condition, open and under way.
- More trials run by Jonsson Comprehensive Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- AIM 1: Previous scan data from healthy subjects is collected and analyzed. AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis. AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection.
- Masking
- None (open label)
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- United States Department of Defense
- Responsible party
- Sponsor
- Investigators
- Benjamin M Ellingson, Principal investigator, UCLA / Jonsson Comprehensive Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05045027
- Sponsor's protocol ID
- 21-000514
- Other IDs
- NCI-2021-08698
- Status last verified
- Nov 2025
- First submitted
- 7 Sep 2021
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Simultaneous Multinuclear (Na+/H+) Metabolic MRI in Brain Tumors
- ClinicalTrials.gov ID
- NCT05045027
- Acronym / sponsor ID
- 21-000514
- Conditions
- Glioma, Malignant Glioma, Recurrent Glioma, Recurrent Malignant Glioma
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 36 participants (actual)
- Lead sponsor
- Jonsson Comprehensive Cancer CenterUniversity, hospital or other
- Collaborators
- United States Department of Defense
- Study start
- 1 Sep 2021 (actual)
- Primary completion
- 15 Nov 2023 (actual)
- Study completion
- 10 Sep 2027 (estimated)
- First posted
- 16 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.
Detailed description
PRIMARY OBJECTIVES:
- Construct and test a novel multinuclear Na+-H+ metabolic MRI sequence with sensitivity to Sodium (Na+) concentration, Potential of Hydrogen (pH), and oxygen (O2).
II. Correlate Na+-, pH-, and O2-weighted MR image measurements with sodium-proton exchanger isoform-1 (NHE1) immunohistochemistry (IHC), bioenergetics, and gene expression using stereotactic image-guided biopsies from human brain tumors.
III. Quantify changes in Na+-, pH-, and O2-weighted MR images after neoadjuvant anti-PD-1 immunotherapy in recurrent glioblastoma (GBM) and explore associated changes in tumor biology.
OUTLINE:
AIM 1: Previous scan data from healthy subjects is collected and analyzed.
AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis.
AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- AIM 1: Previous scan data from healthy subjects is collected and analyzed. AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis. AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection.
| Arm | Type | Receives |
|---|---|---|
| Basic science (MRI, metabolic imaging, tissue collection) | Experimental | Procedure: Biospecimen Collection, Procedure: Diagnostic Imaging, Procedure: Magnetic Resonance ImagingAIM 1: Previous scan data from healthy subjects is collected and analyzed. AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis. AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- AIM 1: Healthy volunteers with no evidence of brain tumors or neurologic disease
- AIM 1: Age 18+
- AIM 2: Newly diagnosed or recurrent suspected or confirmed glioma (low or high grade)
- AIM 2: 10 IDH mutant and 10 IDH wild type gliomas
- AIM 2: Clinically indicated for resective surgery or biopsy
Key exclusion criteria (6 listed)
- AIM 1: Cannot safely perform an MRI
- AIM 1: Age < 18
- AIM 2: Cannot safely perform an MRI or use of MRI contrast agents
- AIM 2: Age < 18
- AIM 3: Cannot safely perform an MRI or use of MRI contrast agents
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biospecimen CollectionAlso: Biological Sample CollectionUndergo collection of tissue samples | Procedure or surgery | Basic science (MRI, metabolic imaging, tissue collection) |
| Diagnostic ImagingAlso: Medical ImagingUndergo multinuclear metabolic imaging | Procedure or surgery | Basic science (MRI, metabolic imaging, tissue collection) |
| Magnetic Resonance ImagingAlso: Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRIUndergo MRI | Procedure or surgery | Basic science (MRI, metabolic imaging, tissue collection) |
Primary outcome
Total sodium concentration
Time frame: Up to 5 years
Will calculate NaT using standard methodology and normalize it to ocular Na+ concentration, a constant 135 mmol/l. Will then test whether healthy tissue has a coefficient of variance (COV) of < 10% across all 20 subjects.
NHE1 expression
Time frame: Up to 5 years
Will create a comprehensive map of genes/pathways and unique cell subsets associated with NHE1 expression.
Tumor metabolism
Time frame: Up to 5 years
Will examine the correlation between baseline tumor metabolism and change in metabolism with respect to overall survival using Cox multivariable regression.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
Related trials for Glioma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Low Grade Astrocytoma, Low Grade Glioma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benjamin M Ellingson principal investigator
UCLA / Jonsson Comprehensive Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Biospecimen Collection, Diagnostic Imaging and Magnetic Resonance Imaging in people with Glioma and Malignant Glioma, run by Jonsson Comprehensive Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total sodium concentration (time frame: Up to 5 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.